Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Jazz Pharmaceuticals (DE:J7Z)
FRANKFURT:J7Z
Holding DE:J7Z?
Track your performance easily
J7Z Stock Chart & Stats
Day’s Range― - ―
52-Week Range€92.40 - €122.90
Previous CloseN/A
Volume0.00
Average Volume (3M)212.00
Market Cap
$7.02B
Enterprise Value€10.62B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)16.7
Beta0.31
Next Earnings
Mar 04, 2025EPS Estimate
5.52Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)6.94
Shares Outstanding60,454,594
10 Day Avg. Volume16
30 Day Avg. Volume212
Standard DeviationN/A
R-SquaredN/A
AlphaN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)1.85
Price to Cash Flow (P/CF)4.60
P/FCF Ratio4.80
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€172.12Price Target Upside45.68% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering16
Jazz Pharmaceuticals News
PremiumCompany Announcements
Jazz Pharmaceuticals Announces CEO Bruce Cozadd’s Retirement Plan
Bulls Say, Bears Say
Bulls Say
Financial PerformanceRecord 3Q $1,055M revenue reiterated with Xywav and Epidiolex beating consensus.
Intellectual Property And PatentsJAZZ has a handful of MOU patents for Clobazam DDI & more recently JAZZ filed another new patent on Epidiolex's DDI with everolimus, which can help extend the patent life to 2030+.
Product Launch And Market PositionThe recent launch of Ziihera with a price close to estimates and its inclusion in NCCN guidelines reflects management's confidence in its success.
Bears Say
Competitive PressureOutlook for Xywav in narcolepsy and IH faces challenges with entry of generics and other competitors.
Legal ChallengesThe 2H25 setup could be trickier, given OX2 data from ALKS and lawsuits including the anti-trust one vs AVDL.
Oncology Revenue ConcernsThe oncology sales guidance range was lowered, suggesting potential challenges in this segment.
---
Options Prices
Currently, No data available
---
Ownership Overview
3.32% Insiders
26.50% Mutual Funds
4.23% Other Institutional Investors
38.50% Public Companies and Individual Investors
J7Z FAQ
What was Jazz Pharmaceuticals’s price range in the past 12 months?
Jazz Pharmaceuticals lowest stock price was €92.40 and its highest was €122.90 in the past 12 months.
What is Jazz Pharmaceuticals’s market cap?
Jazz Pharmaceuticals’s market cap is $7.02B.
When is Jazz Pharmaceuticals’s upcoming earnings report date?
Jazz Pharmaceuticals’s upcoming earnings report date is Mar 04, 2025 which is in 32 days.
How were Jazz Pharmaceuticals’s earnings last quarter?
Jazz Pharmaceuticals released its earnings results on Nov 06, 2024. The company reported €6.353 earnings per share for the quarter, beating the consensus estimate of €5.285 by €1.069.
Is Jazz Pharmaceuticals overvalued?
According to Wall Street analysts Jazz Pharmaceuticals’s price is currently Undervalued.
Does Jazz Pharmaceuticals pay dividends?
Jazz Pharmaceuticals does not currently pay dividends.
What is Jazz Pharmaceuticals’s EPS estimate?
Jazz Pharmaceuticals’s EPS estimate is 5.52.
How many shares outstanding does Jazz Pharmaceuticals have?
Jazz Pharmaceuticals has 60,454,594 shares outstanding.
What happened to Jazz Pharmaceuticals’s price movement after its last earnings report?
Jazz Pharmaceuticals reported an EPS of €6.353 in its last earnings report, beating expectations of €5.285. Following the earnings report the stock price went up 6.425%.
Which hedge fund is a major shareholder of Jazz Pharmaceuticals?
Currently, no hedge funds are holding shares in DE:J7Z
---
Jazz Pharmaceuticals Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
€172.12 (45.68% Upside)
€172.12 (45.68% Upside)
Blogger Sentiment
Bullish
DE:J7Z Sentiment 100%
Sector Average 71%
Sector Average 71%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-0.89%
12-Months-Change
Fundamentals
Return on Equity
12.09%
Trailing 12-Months
Asset Growth
9.39%
Trailing 12-Months
Company Description
Jazz Pharmaceuticals
Jazz Pharmaceuticals Plc operates as a specialty biopharmaceutical company, which focuses on the identification, development and commercialization of pharmaceutical products in the areas of narcolepsy, oncology, pain and psychiatry. Its product portfolio includes: XYREM, ERWINAZETM, PRIALT, intrathecal infusion, FAZACLO and LUVOX CR. The company was founded by Bruce C. Cozadd in March 2003 and is headquartered in Dublin, Ireland.
---
J7Z Company Deck
---
J7Z Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call reflected strong performance across Jazz Pharmaceuticals' commercial portfolio, particularly in neuroscience and oncology, with record sales and positive clinical trial results for Zepzelca. However, there were challenges with Rylaze revenue due to updated treatment protocols and a trial setback for Epidiolex in Japan. Overall, the positive financial results and growth prospects balanced out the highlighted challenges.Read More>---
J7Z Stock 12 Month Forecast
Average Price Target
€172.12
▲(45.68% Upside)
Technical Analysis
ACADIA Pharmaceuticals
―
Neurocrine
―
Supernus Pharmaceuticals
―
Heron Therapeutics
―
SAGE Therapeutics
―
Best Analysts Covering J7Z
1 Year
1 Year Success Rate
19/26 ratings generated profit
1 Year Average Return
+6.12%
reiterated a buy rating 2 months ago
Copying Annabel Samimy's trades and holding each position for 1 Year would result in 73.08% of your transactions generating a profit, with an average return of +6.12% per trade.
---